Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Inhaled immunotherapy shows promise for canine lung cancer
The study used interleukin-15 to reinvigorate the immune system.

Research could also have benefits for humans with the disease. 

US researchers have discovered that a protein naturally produced by the body could become a vital new immunotherapy drug in the fight against cancer.

Scientists at UC Davis and other institutions conducted a trial on 21 dogs with metastatic lung disease from osteosarcoma and melanoma. For 14 days, the dogs inhaled a mist containing interleukin-15 (IL-15) - a protein previously recognised for its immunotherapy properties.

The results, published in the Journal for ImmunoTherapy of Cancer, show that amplified concentrations of IL-15 can stimulate immune system defenses against some types of cancers in dogs. 

“No one previously had administered IL-15 as an inhaled treatment in dogs to deliver it directly to the site of the cancer,” explained Dr Rober Canter, a surgical oncologist at UC Davis Comprehensive Cancer Center. “We came up with that idea as a means of reducing exposure to the rest of the body, in order to improve the benefit-risk ratio, to improve the immune stimulating effects, and to reduce toxicity.”

“In this study, we used interleukin-15 to reinvigorate the immune system to make it recognize the cancer cells that had evaded the immune system and eliminate them.”

In the first-of-its-kind trial, the dogs began to show significant responses to the protein two weeks after they begain inhaling the mist. 

In two dogs, tumours shrank dramatically – including one that went into complete remission for more than a year. Furthermore, cancer that had been growing rapidly in five other dogs stabilised for several months - with the overall response rate being close to 40 per cent.

While more research is yet to be carried out, the team hopes that its findings will also benefit humans with advanced metastatic cancer.

“As part of our comparative oncology research, we are strong advocates of clinical trials in companion dogs, especially for immunotherapy, as a way to speed bench-to-bedside translation,” added Dr Canter. “The cancers that afflict dogs, including sarcomas, brain tumors, lymphoma and melanoma, are incredibly similar to cancers that humans develop.” 

Become a member or log in to add this story to your CPD history

Laura Muir wins gold at Commonwealth Games

News Story 1
 Veterinary surgeon and Olympic silver-medalist Laura Muir scooped the gold medal in the 1500m final Commonwealth Games on Sunday.

Winning Scotland's 12th title of the games, Muir finished in four minutes 2.75 seconds, collecting her second medal in 24 hours.

Dr Muir commented on her win: "I just thought my strength is in my kick and I just tried to trust it and hope nobody would catch me. I ran as hard as I could to the line.

"It is so nice to come here and not just get one medal but two and in such a competitive field. Those girls are fast. It means a lot." 

Click here for more...
News Shorts
Views sought on NOAH Compendium

Users of the National Office of Animal Health (NOAH) Compendium app and website are being asked to share their views on how it can be improved.

In a new survey, users are asked about some suggested future developments, such as notifications for new and updated datasheets, sharing links to datasheets, and enhanced search functionality.

It comes after NOAH ceased publication of the NOAH Compendium book as part of its sustainability and environmental commitments. The website and the app will now be the main routes to access datasheets and view any changes.